Gene Delivery
Partnership
Approach
About
News
Blog
Menu
Close
JPM: Roche Licenses Dyno Therapeutics’ AAV Vector for Neurological Gene Therapy
Press
January 15, 2025
Gen Eng News
TOC LINK
TOC LINK
Press
Published
January 15, 2025
More like this
Dyno Therapeutics Announces Inaugural 2025 Genetic Agency Technology Conference and Launch of Dyno Frontiers Program to Accelerate Progress in Patient-Empowering Gene Therapies
Announcements
Dyno Therapeutics
May 14, 2025
Dyno Therapeutics Announces Inaugural 2025 Genetic Agency Technology Conference and Launch of Dyno Frontiers Program to Accelerate Progress in Patient-Empowering Gene Therapies
Announcements
Dyno Therapeutics
May 14, 2025
Dyno Therapeutics Launches Three Breakthrough Capsid Delivery Vectors for Next-Generation Eye, Muscle and CNS Gene Therapies at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Announcements
Dyno Therapeutics
May 14, 2025
Dyno Therapeutics Launches Three Breakthrough Capsid Delivery Vectors for Next-Generation Eye, Muscle and CNS Gene Therapies at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Announcements
Dyno Therapeutics
May 14, 2025
Dyno Therapeutics to Present Breakthrough Data on AAV Gene Delivery to the CNS, Eye, and Muscle at the 28th Annual Meeting of the American Society of Gene & Cell Therapy
Events
April 28, 2025
Dyno Therapeutics to Present Breakthrough Data on AAV Gene Delivery to the CNS, Eye, and Muscle at the 28th Annual Meeting of the American Society of Gene & Cell Therapy
Events
April 28, 2025
Low-N OpenFold fine-tuning improves peptide design without additional structures
Publications
NeurIPS MLSB
October 4, 2024
Low-N OpenFold fine-tuning improves peptide design without additional structures
Publications
NeurIPS MLSB
October 4, 2024
343 Arsenal St
Watertown, MA 02472
© Dyno 2024
Privacy Policy
Terms + Conditions